{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T04:23:30Z","timestamp":1752985410403,"version":"3.40.3"},"publisher-location":"Cham","reference-count":194,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030963750"},{"type":"electronic","value":"9783030963767"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-030-96376-7_8","type":"book-chapter","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:13:39Z","timestamp":1652346819000},"page":"225-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia"],"prefix":"10.1007","author":[{"given":"Fabiana","family":"Perna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel R.","family":"Espinoza-Gutarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Bombaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif S.","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"1","key":"8_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","volume":"119","author":"GM Dores","year":"2012","unstructured":"Dores GM et al (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007. Blood 119(1):34\u201343","journal-title":"Blood"},{"issue":"4","key":"8_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjh.12425","volume":"162","author":"A Shah","year":"2013","unstructured":"Shah A et al (2013) Survival and cure of acute myeloid leukaemia in England, 1971\u20132006: a population-based study. Br J Haematol 162(4):509\u2013516","journal-title":"Br J Haematol"},{"issue":"4","key":"8_CR3","first-page":"485","volume":"57","author":"JW Yates","year":"1973","unstructured":"Yates JW et al (1973) Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57(4):485\u2013488","journal-title":"Cancer Chemother Rep"},{"issue":"22","key":"8_CR4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","volume":"309","author":"GW Santos","year":"1983","unstructured":"Santos GW et al (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309(22):1347\u20131353","journal-title":"N Engl J Med"},{"issue":"19","key":"8_CR5","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","volume":"300","author":"PL Weiden","year":"1979","unstructured":"Weiden PL et al (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300(19):1068\u20131073","journal-title":"N Engl J Med"},{"issue":"12","key":"8_CR6","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","volume":"76","author":"H Kolb","year":"1990","unstructured":"Kolb H et al (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12):2462\u20132465","journal-title":"Blood"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1182\/asheducation-2013.1.201","volume":"2013","author":"GJ Schiller","year":"2013","unstructured":"Schiller GJ (2013) High-risk acute myelogenous leukemia: treatment today \u2026 and tomorrow. Hematology Am Soc Hematol Educ Program 2013:201\u2013208","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"8_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"5","key":"8_CR9","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.cell.2015.07.045","volume":"162","author":"JD Wolchok","year":"2015","unstructured":"Wolchok JD (2015) PD-1 blockers. Cell 162(5):937","journal-title":"Cell"},{"issue":"8","key":"8_CR10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","volume":"114","author":"L Zhang","year":"2009","unstructured":"Zhang L, Gajewski TF, Kline J (2009) PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114(8):1545\u20131552","journal-title":"Blood"},{"issue":"22","key":"8_CR11","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood.V128.22.2900.2900","volume":"128","author":"N Daver","year":"2016","unstructured":"Daver N et al (2016) Defining the immune checkpoint landscape in patients (pts) with Acute Myeloid Leukemia (AML). Blood 128(22):2900\u20132900","journal-title":"Blood"},{"issue":"1","key":"8_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","volume":"13","author":"C Chen","year":"2020","unstructured":"Chen C et al (2020) Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol 13(1):28","journal-title":"J Hematol Oncol"},{"issue":"10","key":"8_CR13","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"Berger R et al (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14(10):3044\u20133051","journal-title":"Clin Cancer Res"},{"issue":"2","key":"8_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS et al (2016) Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 375(2):143\u2013153","journal-title":"N Engl J Med"},{"issue":"3","key":"8_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-021-00453-z","volume":"11","author":"PK Reville","year":"2021","unstructured":"Reville PK et al (2021) Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60","journal-title":"Blood Cancer J"},{"issue":"9","key":"8_CR16","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","volume":"6","author":"F Ravandi","year":"2019","unstructured":"Ravandi F et al (2019) Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480\u2013e488","journal-title":"Lancet Haematol"},{"issue":"3","key":"8_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N et al (2019) Efficacy, safety, and biomarkers of response to azacitidine and Nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov 9(3):370","journal-title":"Cancer Discov"},{"key":"8_CR18","doi-asserted-by":"crossref","unstructured":"Acharya N, Sabatos-Peyton C, Anderson AC (2020) Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer 8(1)","DOI":"10.1136\/jitc-2020-000911"},{"issue":"12","key":"8_CR19","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M et al (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A 108(12):5009\u20135014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S et al (2019) Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33(1):64\u201374","journal-title":"Leukemia"},{"issue":"51","key":"8_CR21","doi-asserted-by":"publisher","first-page":"88904","DOI":"10.18632\/oncotarget.21492","volume":"8","author":"T Asayama","year":"2017","unstructured":"Asayama T et al (2017) Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget 8(51):88904\u201388917","journal-title":"Oncotarget"},{"key":"8_CR22","unstructured":"Borate U et al (2020) Anti-TIM-3 antibody MBG453 in combination with hypomethylating agents in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia: a phase 1 study. In: Abstract presented at: the 25th European Hematology Association Congress"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","volume":"9","author":"MP Chao","year":"2019","unstructured":"Chao MP et al (2019) Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol 9:1380","journal-title":"Front Oncol"},{"key":"8_CR24","doi-asserted-by":"crossref","unstructured":"Molica M et al (2021) TP53 mutations in acute myeloid leukemia: still a daunting challenge? Front Oncol 10(3368)","DOI":"10.3389\/fonc.2020.610820"},{"key":"8_CR25","doi-asserted-by":"crossref","unstructured":"Sallman DA et al (2020) Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results. J Clin Oncol 38(15_suppl):7507\u20137507","DOI":"10.1200\/JCO.2020.38.15_suppl.7507"},{"issue":"23","key":"8_CR26","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221","journal-title":"N Engl J Med"},{"key":"8_CR27","doi-asserted-by":"crossref","unstructured":"Rizvi NA et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124\u2013128","DOI":"10.1126\/science.aaa1348"},{"issue":"6280","key":"8_CR28","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463\u20131469","journal-title":"Science"},{"issue":"7463","key":"8_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415\u2013421","journal-title":"Nature"},{"issue":"6257","key":"8_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM et al (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207\u2013211","journal-title":"Science"},{"issue":"7457","key":"8_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214\u2013218","journal-title":"Nature"},{"issue":"5","key":"8_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMoa0811036","volume":"361","author":"L Vago","year":"2009","unstructured":"Vago L et al (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361(5):478\u2013488","journal-title":"N Engl J Med"},{"issue":"3","key":"8_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL (2015) Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 93(3):290\u2013296","journal-title":"Immunol Cell Biol"},{"key":"8_CR34","doi-asserted-by":"crossref","unstructured":"Ross SL et al (2017) Bispecific T cell engager (BiTE(R)) antibody constructs can mediate bystander tumor cell killing. PLoS One. 12(8):e0183390","DOI":"10.1371\/journal.pone.0183390"},{"issue":"6","key":"8_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","volume":"13","author":"DG Guy","year":"2018","unstructured":"Guy DG, Uy GL (2018) Bispecific antibodies for the treatment of acute myeloid leukemia. Curr Hematol Malig Rep 13(6):417\u2013425","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"8_CR36","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","volume":"123","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS et al (2014) Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123(4):554\u2013561","journal-title":"Blood"},{"key":"8_CR37","doi-asserted-by":"crossref","unstructured":"Ravandi F et al (2020) Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). J Clin Oncol 38(15_suppl):7508\u20137508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508"},{"issue":"3","key":"8_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka C et al (2014) CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 123(3):356\u2013365","journal-title":"Blood"},{"issue":"6","key":"8_CR39","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","volume":"13","author":"M Friedrich","year":"2014","unstructured":"Friedrich M et al (2014) Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 13(6):1549\u20131557","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"8_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","volume":"6","author":"R Jitschin","year":"2018","unstructured":"Jitschin R et al (2018) CD33\/CD3-bispecific T-cell engaging (BiTE(R)) antibody construct targets monocytic AML myeloid-derived suppressor cells. J Immunother Cancer 6(1):116","journal-title":"J Immunother Cancer"},{"issue":"23","key":"8_CR41","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","volume":"132","author":"M Herrmann","year":"2018","unstructured":"Herrmann M et al (2018) Bifunctional PD-1 x alphaCD3 x alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood 132(23):2484\u20132494","journal-title":"Blood"},{"key":"8_CR42","doi-asserted-by":"crossref","unstructured":"Chichili GR et al (2015) A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med 7(289):289ra82","DOI":"10.1126\/scitranslmed.aaa5693"},{"issue":"4","key":"8_CR43","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1080\/10428194.2017.1361023","volume":"59","author":"NM Cruz","year":"2018","unstructured":"Cruz NM et al (2018) Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. Leuk Lymphoma 59(4):978\u2013982","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"8_CR44","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan CT et al (2000) The IL-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14(10):1777\u20131784","journal-title":"Leukemia"},{"issue":"8","key":"8_CR45","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","volume":"100","author":"U Testa","year":"2002","unstructured":"Testa U et al (2002) Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100(8):2980\u20132988","journal-title":"Blood"},{"issue":"12","key":"8_CR46","first-page":"1261","volume":"86","author":"L Mu\u00f1oz","year":"2001","unstructured":"Mu\u00f1oz L et al (2001) IL-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86(12):1261\u20131269","journal-title":"Haematologica"},{"key":"8_CR47","doi-asserted-by":"crossref","unstructured":"Godwin JE et al (2019) Flotetuzumab (FLZ), an investigational CD123 x CD3 bispecific Dart\u00ae protein-induced clustering of CD3+ T cells and CD123+ AML cells in bone marrow biopsies is associated with response to treatment in primary refractory AML patients. Blood 134(Supplement_1):1410\u20131410","DOI":"10.1182\/blood-2019-128485"},{"key":"8_CR48","unstructured":"Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)"},{"issue":"20","key":"8_CR49","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","volume":"4","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J et al (2020) TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv 4(20):5011\u20135024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"8_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2020-134576","volume":"136","author":"I Aldoss","year":"2020","unstructured":"Aldoss I et al (2020) Flotetuzumab as salvage therapy for primary induction failure and early relapse acute myeloid leukemia. Blood 136(Supplement 1):16\u201318","journal-title":"Blood"},{"key":"8_CR51","doi-asserted-by":"crossref","unstructured":"Braciak TA et al (2018) Dual-targeting triplebody 33\u201316\u2013123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. Oncoimmunology 7(9):e1472195","DOI":"10.1080\/2162402X.2018.1472195"},{"issue":"21","key":"8_CR52","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood.V124.21.2316.2316","volume":"124","author":"SY Chu","year":"2014","unstructured":"Chu SY et al (2014) Immunotherapy with long-lived anti-CD123 \u00d7 anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Blood 124(21):2316\u20132316","journal-title":"Blood"},{"issue":"Supplement 1","key":"8_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-134746","volume":"136","author":"F Ravandi","year":"2020","unstructured":"Ravandi F et al (2020) Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study. Blood 136(Supplement 1):4\u20135","journal-title":"Blood"},{"issue":"9","key":"8_CR54","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1158\/1535-7163.MCT-15-0242","volume":"15","author":"G Hernandez-Hoyos","year":"2016","unstructured":"Hernandez-Hoyos G et al (2016) MOR209\/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther 15(9):2155\u20132165","journal-title":"Mol Cancer Ther"},{"issue":"13 Supplement","key":"8_CR55","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1538-7445.AM2018-1786","volume":"78","author":"MR Comeau","year":"2018","unstructured":"Comeau MR et al (2018) Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR\u2122 molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release. Can Res 78(13 Supplement):1786","journal-title":"Can Res"},{"key":"8_CR56","unstructured":"Study of APVO436 in Patients With AML or MDS"},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ (2019) Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev 34:26\u201333","journal-title":"Blood Rev"},{"issue":"20","key":"8_CR58","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1089\/scd.2016.0310","volume":"26","author":"YY Wang","year":"2017","unstructured":"Wang YY et al (2017) Low CLL-1 expression Is a novel adverse predictor in 123 patients with De Novo CD34(+) acute myeloid leukemia. Stem Cells Dev 26(20):1460\u20131467","journal-title":"Stem Cells Dev"},{"issue":"8","key":"8_CR59","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","volume":"21","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A et al (2007) Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21(8):1700\u20131707","journal-title":"Leukemia"},{"issue":"6","key":"8_CR60","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/CJI.0b013e3181dda225","volume":"33","author":"H Singer","year":"2010","unstructured":"Singer H et al (2010) Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 33(6):599\u2013608","journal-title":"J Immunother"},{"issue":"19","key":"8_CR61","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","volume":"123","author":"MK Gleason","year":"2014","unstructured":"Gleason MK et al (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123(19):3016\u20133026","journal-title":"Blood"},{"key":"8_CR62","unstructured":"GT Biopharma I (2021) GT biopharma announces interim GTB-3550 TRIKE\u2122 monotherapy clinical trial results AT 2021 Raymond James human health innovation conference. Available from: https:\/\/www.gtbiopharma.com\/news-media\/press-releases\/detail\/225\/gt-biopharma-announces-interim-gtb-3550-trike"},{"issue":"9","key":"8_CR63","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Mackall CL (2019) Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med 25(9):1341\u20131355","journal-title":"Nat Med"},{"issue":"1","key":"8_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah BD et al (2021) KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138(1):11\u201322","journal-title":"Blood"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"MC Jensen","year":"2015","unstructured":"Jensen MC, Riddell SR (2015) Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 33:9\u201315","journal-title":"Curr Opin Immunol"},{"issue":"7655","key":"8_CR66","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain M, Riviere I, Riddell S (2017) Therapeutic T cell engineering. Nature 545(7655):423\u2013431","journal-title":"Nature"},{"key":"8_CR67","doi-asserted-by":"crossref","unstructured":"Zhou G, Levitsky H (2012) Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol 2012:124187","DOI":"10.1155\/2012\/124187"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL et al (2017) Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 4:92\u2013101","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"8_CR69","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","volume":"26","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff CA et al (2005) Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26(2):111\u2013117","journal-title":"Trends Immunol"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fonc.2020.00262","volume":"10","author":"R Epperly","year":"2020","unstructured":"Epperly R, Gottschalk S, Velasquez MP (2020) A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy. Front Oncol 10:262","journal-title":"Front Oncol"},{"issue":"9","key":"8_CR71","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J et al (2017) Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 9(9):1183\u20131197","journal-title":"EMBO Mol Med"},{"issue":"11","key":"8_CR72","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie DS et al (2013) Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 21(11):2122\u20132129","journal-title":"Mol Ther"},{"issue":"1","key":"8_CR73","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"QS Wang","year":"2015","unstructured":"Wang QS et al (2015) Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23(1):184\u2013191","journal-title":"Mol Ther"},{"key":"8_CR74","doi-asserted-by":"crossref","unstructured":"Tambaro FP et al (2021) Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia","DOI":"10.1038\/s41375-021-01232-2"},{"issue":"4","key":"8_CR75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","volume":"101","author":"M Redman","year":"2016","unstructured":"Redman M et al (2016) What is CRISPR\/Cas9? Arch Dis Child Educ Pract Ed 101(4):213\u2013215","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"24","key":"8_CR76","doi-asserted-by":"publisher","first-page":"11978","DOI":"10.1073\/pnas.1819992116","volume":"116","author":"F Borot","year":"2019","unstructured":"Borot F et al (2019) Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc Natl Acad Sci U S A 116(24):11978\u201311987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"8_CR77","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.ymthe.2020.05.021","volume":"28","author":"MC Rotiroti","year":"2020","unstructured":"Rotiroti MC et al (2020) Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system. Mol Ther 28(9):1974\u20131986","journal-title":"Mol Ther"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","volume":"17","author":"S Loff","year":"2020","unstructured":"Loff S et al (2020) Rapidly switchable universal CAR-T cells for treatment of CD123-positive Leukemia. Mol Ther Oncolytics 17:408\u2013420","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"8_CR79","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J et al (2018) CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol 11(1):7","journal-title":"J Hematol Oncol"},{"issue":"4","key":"8_CR80","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer T et al (2021) CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 138(4):318\u2013330","journal-title":"Blood"},{"issue":"Supplement 1","key":"8_CR81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-142745","volume":"136","author":"E Shrestha","year":"2020","unstructured":"Shrestha E et al (2020) Preclinical development of anti-FLT3 CAR-T therapy for the treatment of acute myeloid leukemia. Blood 136(Supplement 1):4\u20135","journal-title":"Blood"},{"key":"8_CR82","doi-asserted-by":"crossref","unstructured":"Mardiana S, Gill S (2020) CAR T cells for acute myeloid Leukemia: state of the art and future directions. Front Oncol 10(697)","DOI":"10.3389\/fonc.2020.00697"},{"key":"8_CR83","unstructured":"Study evaluating safety and efficacy of CAR-T cells targeting CD123 in patients with acute myelocytic Leukemia"},{"key":"8_CR84","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","volume":"9","author":"S Yao","year":"2019","unstructured":"Yao S et al (2019) Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML. Front Oncol 9:1358","journal-title":"Front Oncol"},{"issue":"1","key":"8_CR85","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH et al (2019) Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res 7(1):100\u2013112","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"8_CR86","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","volume":"14","author":"Q Cui","year":"2021","unstructured":"Cui Q et al (2021) CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol 14(1):82","journal-title":"J Hematol Oncol"},{"key":"8_CR87","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1034\/j.1600-065X.2000.17701.x","volume":"177","author":"BS Youn","year":"2000","unstructured":"Youn BS, Mantel C, Broxmeyer HE (2000) Chemokines, chemokine receptors and hematopoiesis. Immunol Rev 177:150\u2013174","journal-title":"Immunol Rev"},{"issue":"9","key":"8_CR88","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","volume":"25","author":"H Tashiro","year":"2017","unstructured":"Tashiro H et al (2017) Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther 25(9):2202\u20132213","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"8_CR89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2020-140648","volume":"136","author":"C Bu","year":"2020","unstructured":"Bu C et al (2020) Phase I clinical trial of autologous CLL1 CAR-T therapy for pediatric patients with relapsed and refractory acute myeloid leukemia. Blood 136(Supplement 1):13\u201313","journal-title":"Blood"},{"key":"8_CR90","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F et al (2018) First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood 132:901","journal-title":"Blood"},{"issue":"5","key":"8_CR91","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","volume":"32","author":"H Jetani","year":"2018","unstructured":"Jetani H et al (2018) CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 32(5):1168\u20131179","journal-title":"Leukemia"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/978-1-4939-3387-7_43","volume":"1403","author":"S Thomas","year":"2016","unstructured":"Thomas S, Prendergast GC (2016) Cancer vaccines: a brief overview. Methods Mol Biol 1403:755\u2013761","journal-title":"Methods Mol Biol"},{"issue":"4","key":"8_CR93","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1586\/14760584.4.4.503","volume":"4","author":"H Sugiyama","year":"2005","unstructured":"Sugiyama H (2005) Cancer immunotherapy targeting Wilms\u2019 tumor gene WT1 product. Expert Rev Vaccines 4(4):503\u2013512","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"8_CR94","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/sj.leu.2403186","volume":"18","author":"V Mail\u00e4nder","year":"2004","unstructured":"Mail\u00e4nder V et al (2004) Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematologic or renal toxicity. Leukemia 18(1):165\u2013166","journal-title":"Leukemia"},{"key":"8_CR95","doi-asserted-by":"crossref","unstructured":"Di Stasi A et al (2015) Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 6(36)","DOI":"10.3389\/fimmu.2015.00036"},{"issue":"6","key":"8_CR96","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/leu.2011.343","volume":"26","author":"A Tsuboi","year":"2012","unstructured":"Tsuboi A et al (2012) Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 26(6):1410\u20131413","journal-title":"Leukemia"},{"issue":"26","key":"8_CR97","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","volume":"113","author":"U Keilholz","year":"2009","unstructured":"Keilholz U et al (2009) A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113(26):6541\u20136548","journal-title":"Blood"},{"issue":"3","key":"8_CR98","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak PG et al (2018) Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv 2(3):224\u2013234","journal-title":"Blood Adv"},{"issue":"15","key":"8_CR99","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","volume":"130","author":"S Anguille","year":"2017","unstructured":"Anguille S et al (2017) Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood 130(15):1713\u20131721","journal-title":"Blood"},{"issue":"6","key":"8_CR100","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2002-01-0163","volume":"100","author":"C Scheibenbogen","year":"2002","unstructured":"Scheibenbogen C et al (2002) CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100(6):2132\u20132137","journal-title":"Blood"},{"issue":"3","key":"8_CR101","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2016.254","volume":"31","author":"MH Qazilbash","year":"2017","unstructured":"Qazilbash MH et al (2017) PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31(3):697\u2013704","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"8_CR102","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2020-139266","volume":"136","author":"A van de Loosdrecht","year":"2020","unstructured":"van de Loosdrecht A et al (2020) Conversion from MRD positive to negative status in AML patients in CR1 after treatment with an allogeneic leukemia-derived dendritic cell vaccine. Blood 136(Supplement 1):13\u201314","journal-title":"Blood"},{"issue":"37","key":"8_CR103","doi-asserted-by":"publisher","first-page":"15825","DOI":"10.1073\/pnas.0908358106","volume":"106","author":"VT Ho","year":"2009","unstructured":"Ho VT et al (2009) Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 106(37):15825\u201315830","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"8_CR104","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/blood-2008-03-144071","volume":"113","author":"K Rezvani","year":"2009","unstructured":"Rezvani K et al (2009) Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113(10):2245\u20132255","journal-title":"Blood"},{"key":"8_CR105","doi-asserted-by":"crossref","unstructured":"van den Ancker W et al (2013) Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: implications for immunotherapy. Oncoimmunology 2(4):e23971","DOI":"10.4161\/onci.23971"},{"issue":"3","key":"8_CR106","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","volume":"111","author":"M Schmitt","year":"2008","unstructured":"Schmitt M et al (2008) RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111(3):1357\u20131365","journal-title":"Blood"},{"issue":"4","key":"8_CR107","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","volume":"54","author":"G Ehx","year":"2021","unstructured":"Ehx G et al (2021) Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity 54(4):737-752.e10","journal-title":"Immunity"},{"key":"8_CR108","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225\u2013274","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"8_CR109","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-017-0505-0","volume":"10","author":"FS Lichtenegger","year":"2017","unstructured":"Lichtenegger FS et al (2017) Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol 10(1):142","journal-title":"J Hematol Oncol"},{"issue":"2","key":"8_CR110","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18(2):85\u2013100","journal-title":"Nat Rev Clin Oncol"},{"issue":"5562","key":"8_CR111","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097\u20132100","journal-title":"Science"},{"issue":"1","key":"8_CR112","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","volume":"110","author":"L Ruggeri","year":"2007","unstructured":"Ruggeri L et al (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110(1):433\u2013440","journal-title":"Blood"},{"issue":"8","key":"8_CR113","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051\u20133057","journal-title":"Blood"},{"issue":"6","key":"8_CR114","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE et al (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28(6):955\u2013959","journal-title":"J Clin Oncol"},{"issue":"8","key":"8_CR115","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1158\/1078-0432.CCR-15-1604","volume":"22","author":"A Curti","year":"2016","unstructured":"Curti A et al (2016) Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clin Cancer Res 22(8):1914\u20131921","journal-title":"Clin Cancer Res"},{"issue":"6","key":"8_CR116","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1084\/jem.20122462","volume":"210","author":"G Gasteiger","year":"2013","unstructured":"Gasteiger G et al (2013) IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med 210(6):1167\u20131178","journal-title":"J Exp Med"},{"issue":"25","key":"8_CR117","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova V et al (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123(25):3855\u20133863","journal-title":"Blood"},{"issue":"12","key":"8_CR118","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/14740338.2017.1382472","volume":"16","author":"S Marabondo","year":"2017","unstructured":"Marabondo S, Kaufman HL (2017) High-dose IL-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf 16(12):1347\u20131357","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"8_CR119","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood-2001-12-0293","volume":"100","author":"MA Cooper","year":"2002","unstructured":"Cooper MA et al (2002) In vivo evidence for a dependence on IL-15 for survival of natural killer cells. Blood 100(10):3633\u20133638","journal-title":"Blood"},{"issue":"13","key":"8_CR120","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","volume":"3","author":"S Cooley","year":"2019","unstructured":"Cooley S et al (2019) First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv 3(13):1970\u20131980","journal-title":"Blood Adv"},{"issue":"8","key":"8_CR121","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","volume":"24","author":"AT Bj\u00f6rklund","year":"2018","unstructured":"Bj\u00f6rklund AT et al (2018) Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clin Cancer Res 24(8):1834\u20131844","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8_CR122","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4049\/jimmunol.178.1.85","volume":"178","author":"J North","year":"2007","unstructured":"North J et al (2007) Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol 178(1):85\u201394","journal-title":"J Immunol"},{"issue":"8","key":"8_CR123","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","volume":"24","author":"TA Fehniger","year":"2018","unstructured":"Fehniger TA et al (2018) A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 24(8):1581\u20131589","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"8_CR124","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","volume":"69","author":"H Fujisaki","year":"2009","unstructured":"Fujisaki H et al (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69(9):4010\u20134017","journal-title":"Cancer Res"},{"key":"8_CR125","doi-asserted-by":"crossref","unstructured":"Denman CJ et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7(1):e30264","DOI":"10.1371\/journal.pone.0030264"},{"issue":"16","key":"8_CR126","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","volume":"130","author":"SO Ciurea","year":"2017","unstructured":"Ciurea SO et al (2017) Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood 130(16):1857\u20131868","journal-title":"Blood"},{"issue":"15","key":"8_CR127","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","volume":"23","author":"H Dolstra","year":"2017","unstructured":"Dolstra H et al (2017) Successful transfer of umbilical cord blood CD34(+) hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. Clin Cancer Res 23(15):4107\u20134118","journal-title":"Clin Cancer Res"},{"key":"8_CR128","doi-asserted-by":"crossref","unstructured":"Spanholtz, J., et al., Clinical-Grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One, 2011. 6(6): p. e20740.","DOI":"10.1371\/journal.pone.0020740"},{"key":"8_CR129","doi-asserted-by":"crossref","unstructured":"Cany J et al (2013) Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD\/SCID\/IL2Rg(null) mice. PLoS One 8(6):e64384","DOI":"10.1371\/journal.pone.0064384"},{"issue":"9","key":"8_CR130","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"GP Adams","year":"2005","unstructured":"Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147\u20131157","journal-title":"Nat Biotechnol"},{"key":"8_CR131","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.cellbio.12.1.181","volume":"12","author":"M Raghavan","year":"1996","unstructured":"Raghavan M, Bjorkman PJ (1996) Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 12:181\u2013220","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"3","key":"8_CR132","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamaoncol.2016.4884","volume":"3","author":"PG Gavin","year":"2017","unstructured":"Gavin PG et al (2017) Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2\/HER2\u2013positive breast cancer. JAMA Oncol 3(3):335","journal-title":"JAMA Oncol"},{"key":"8_CR133","volume-title":"DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology","author":"VT DeVita","year":"2008","unstructured":"DeVita VT, Lawrence TS, Rosenberg SA (2008) DeVita, Hellman, and Rosenberg\u2019s cancer: principles and practice of oncology. Wolters Kluwer\/Lippincott Williams & Wilkins, Philadelphia"},{"issue":"4613","key":"8_CR134","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1126\/science.6879183","volume":"221","author":"Z Steplewski","year":"1983","unstructured":"Steplewski Z, Lubeck MD, Koprowski H (1983) Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221(4613):865\u2013867","journal-title":"Science"},{"issue":"4915","key":"8_CR135","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.2787530","volume":"245","author":"BC Trauth","year":"1989","unstructured":"Trauth BC et al (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245(4915):301\u2013305","journal-title":"Science"},{"key":"8_CR136","doi-asserted-by":"crossref","unstructured":"Walport MJ (2001) Complement. First of two parts. N Engl J Med 344(14):1058\u20131066","DOI":"10.1056\/NEJM200104053441406"},{"issue":"12","key":"8_CR137","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3324\/haematol.2011.047159","volume":"96","author":"P Boross","year":"2011","unstructured":"Boross P et al (2011) The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 96(12):1822\u20131830","journal-title":"Haematologica"},{"issue":"4","key":"8_CR138","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","volume":"7","author":"S Li","year":"2005","unstructured":"Li S et al (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4):301\u2013311","journal-title":"Cancer Cell"},{"key":"8_CR139","doi-asserted-by":"crossref","unstructured":"Fenwarth L et al (2020) Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. Int J Mol Sci 21(16)","DOI":"10.3390\/ijms21165626"},{"issue":"24","key":"8_CR140","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH et al (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121(24):4854\u20134860","journal-title":"Blood"},{"issue":"1","key":"8_CR141","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J et al (2019) Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104(1):113\u2013119","journal-title":"Haematologica"},{"issue":"9","key":"8_CR142","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15(9):986\u2013996","journal-title":"Lancet Oncol"},{"key":"8_CR143","doi-asserted-by":"crossref","unstructured":"Cortes JE et al (2020) Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol 13(1)","DOI":"10.1186\/s13045-020-00975-2"},{"issue":"2","key":"8_CR144","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1158\/1078-0432.CCR-20-2149","volume":"27","author":"YC Han","year":"2021","unstructured":"Han YC et al (2021) Development of highly optimized antibody-drug conjugates against CD33 and CD123 for acute myeloid leukemia. Clin Cancer Res 27(2):622\u2013631","journal-title":"Clin Cancer Res"},{"issue":"8","key":"8_CR145","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/protein\/13.8.575","volume":"13","author":"AE Frankel","year":"2000","unstructured":"Frankel AE et al (2000) Characterization of diphtheria fusion proteins targeted to the human IL-3 receptor. Protein Eng 13(8):575\u2013581","journal-title":"Protein Eng"},{"issue":"17","key":"8_CR146","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N et al (2019) Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 380(17):1628\u20131637","journal-title":"N Engl J Med"},{"issue":"14","key":"8_CR147","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1182\/bloodadvances.2020001875","volume":"4","author":"S Yun","year":"2020","unstructured":"Yun S et al (2020) Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Adv 4(14):3435\u20133442","journal-title":"Blood Adv"},{"key":"8_CR148","unstructured":"Tagraxofusp in treating patients with blastic plasmacytoid dendritic cell neoplasm after stem cell transplant"},{"issue":"8","key":"8_CR149","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","volume":"2","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y et al (2018) A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv 2(8):848\u2013858","journal-title":"Blood Adv"},{"key":"8_CR150","doi-asserted-by":"crossref","unstructured":"Daver NG et al (2019) Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC). In: Patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood 134(Supplement_1):734","DOI":"10.1182\/blood-2019-128648"},{"key":"8_CR151","unstructured":"Study of IMGN632 in patients with untreated BPDCN and relapsed\/refractory BPDCN"},{"key":"8_CR152","unstructured":"IMGN632 as monotherapy or with venetoclax and\/or azacitidine for patients with CD123-positive acute myeloid leukemia"},{"key":"8_CR153","doi-asserted-by":"crossref","unstructured":"Liu J et al (2015) Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLOS ONE 10(9):e0137345","DOI":"10.1371\/journal.pone.0137345"},{"key":"8_CR154","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1182\/blood-2018-99-120170","volume":"132","author":"D Feng","year":"2018","unstructured":"Feng D et al (2018) Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia. Blood 132:2729","journal-title":"Blood"},{"issue":"Supplement 1","key":"8_CR155","first-page":"330","volume":"136","author":"D Sallman","year":"2020","unstructured":"Sallman D et al (2020) The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results. Blood 136(Supplement 1):330","journal-title":"Blood"},{"issue":"1","key":"8_CR156","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1600-065X.2009.00774.x","volume":"229","author":"MA Nolte","year":"2009","unstructured":"Nolte MA et al (2009) Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 229(1):216\u2013231","journal-title":"Immunol Rev"},{"issue":"2","key":"8_CR157","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20152008","volume":"214","author":"C Riether","year":"2017","unstructured":"Riether C et al (2017) CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med 214(2):359\u2013380","journal-title":"J Exp Med"},{"issue":"9","key":"8_CR158","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C et al (2020) Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med 26(9):1459\u20131467","journal-title":"Nat Med"},{"key":"8_CR159","doi-asserted-by":"crossref","unstructured":"Trudel GC et al (2020) CULMINATE: a phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy. J Clin Oncol 38(15_suppl):TPS7565","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS7565"},{"key":"8_CR160","unstructured":"Globenewswire. argenx announces 2021 corporate priorities and highlights recent achievements across immunology pipeline. 2021 July 28, 2021]. Available from: https:\/\/www.globenewswire.com\/fr\/news-release\/2021\/01\/08\/2155322\/0\/en\/argenx-Announces-2021-Corporate-Priorities-and-Highlights-Recent-Achievements-Across-Immunology-Pipeline.html"},{"key":"8_CR161","unstructured":"Cusatuzumab in combination with background therapy for the treatment of participants with acute myeloid leukemia"},{"issue":"10","key":"8_CR162","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin L et al (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167\u20131174","journal-title":"Nat Med"},{"issue":"1","key":"8_CR163","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1038\/s41598-020-66806-z","volume":"10","author":"F Liu","year":"2020","unstructured":"Liu F et al (2020) CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma. Sci Rep 10(1):10768","journal-title":"Sci Rep"},{"issue":"1","key":"8_CR164","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","volume":"12","author":"H Ma","year":"2019","unstructured":"Ma H et al (2019) Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol 12(1):41","journal-title":"J Hematol Oncol"},{"key":"8_CR165","doi-asserted-by":"crossref","unstructured":"Anami Y et al (2020) LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia. Mol Cancer Ther","DOI":"10.1158\/1535-7163.MCT-20-0407"},{"key":"8_CR166","doi-asserted-by":"crossref","unstructured":"Saito Y et al (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2(17):17ra9","DOI":"10.1126\/scitranslmed.3000349"},{"key":"8_CR167","first-page":"9593750","volume":"2017","author":"R Mozafari","year":"2017","unstructured":"Mozafari R, Moeinian M, Asadollahi-Amin A (2017) Spontaneous complete remission in a patient with acute myeloid leukemia and severe sepsis. Case Rep Hematol 2017:9593750","journal-title":"Case Rep Hematol"},{"issue":"2","key":"8_CR168","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ymthe.2021.01.011","volume":"29","author":"F Perna","year":"2021","unstructured":"Perna F (2021) Safety starts with selecting the targets. Mol Ther 29(2):424\u2013425","journal-title":"Mol Ther"},{"issue":"15","key":"8_CR169","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","volume":"184","author":"SX Lu","year":"2021","unstructured":"Lu SX et al (2021) Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell 184(15):4032-4047.e31","journal-title":"Cell"},{"issue":"1","key":"8_CR170","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.celrep.2018.03.052","volume":"23","author":"RG Jayasinghe","year":"2018","unstructured":"Jayasinghe RG et al (2018) Systematic analysis of splice-site-creating mutations in cancer. Cell Rep 23(1):270-281.e3","journal-title":"Cell Rep"},{"key":"8_CR171","doi-asserted-by":"crossref","unstructured":"Dong C et al (2021) Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma. Oncogene","DOI":"10.1038\/s41388-021-02005-y"},{"issue":"2","key":"8_CR172","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","volume":"34","author":"A Kahles","year":"2018","unstructured":"Kahles A et al (2018) Comprehensive analysis of alternative splicing across tumors from 8705 patients. Cancer Cell 34(2):211-224.e6","journal-title":"Cancer Cell"},{"key":"8_CR173","unstructured":"(2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32(2):185\u2013203.e13"},{"key":"8_CR174","doi-asserted-by":"crossref","unstructured":"Perna F et al (2017) Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32(4):506\u2013519 e5","DOI":"10.1016\/j.ccell.2017.09.004"},{"key":"8_CR175","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","volume":"8","author":"FM Schnorfeil","year":"2015","unstructured":"Schnorfeil FM et al (2015) T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol 8:93","journal-title":"J Hematol Oncol"},{"issue":"17","key":"8_CR176","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q et al (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117(17):4501\u20134510","journal-title":"Blood"},{"issue":"8","key":"8_CR177","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.leukres.2014.05.014","volume":"38","author":"FS Lichtenegger","year":"2014","unstructured":"Lichtenegger FS et al (2014) Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leuk Res 38(8):964\u2013969","journal-title":"Leuk Res"},{"issue":"6","key":"8_CR178","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25791","volume":"129","author":"Z Shenghui","year":"2011","unstructured":"Shenghui Z et al (2011) Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 129(6):1373\u20131381","journal-title":"Int J Cancer"},{"issue":"13","key":"8_CR179","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","volume":"129","author":"AR Pyzer","year":"2017","unstructured":"Pyzer AR et al (2017) MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 129(13):1791\u20131801","journal-title":"Blood"},{"issue":"8","key":"8_CR180","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/10245332.2015.1106814","volume":"21","author":"I Mansour","year":"2016","unstructured":"Mansour I et al (2016) Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia. Hematology 21(8):447\u2013453","journal-title":"Hematology"},{"issue":"6","key":"8_CR181","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1182\/blood.V99.6.2146","volume":"99","author":"JL LaBelle","year":"2002","unstructured":"LaBelle JL et al (2002) Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7\u20131+, but not B7\u20132+, murine myelogenous leukemia. Blood 99(6):2146\u20132153","journal-title":"Blood"},{"issue":"5","key":"8_CR182","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","volume":"7","author":"X Chen","year":"2008","unstructured":"Chen X et al (2008) Clinical significance of B7\u2013H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther 7(5):622\u2013627","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"8_CR183","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y et al (2010) TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7(6):708\u2013717","journal-title":"Cell Stem Cell"},{"issue":"12","key":"8_CR184","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y et al (2016) T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res 22(12):3057\u20133066","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8_CR185","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12885-020-06961-8","volume":"20","author":"Y Wan","year":"2020","unstructured":"Wan Y et al (2020) Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia. BMC Cancer 20(1):472","journal-title":"BMC Cancer"},{"key":"8_CR186","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","volume":"43","author":"S Binder","year":"2018","unstructured":"Binder S, Luciano M, Horejs-Hoeck J (2018) The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev 43:8\u201315","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"8_CR187","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11899-015-0255-4","volume":"10","author":"A Rashidi","year":"2015","unstructured":"Rashidi A, Uy GL (2015) Targeting the microenvironment in acute myeloid leukemia. Curr Hematol Malig Rep 10(2):126\u2013131","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"8_CR188","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0301-472X(01)00612-9","volume":"29","author":"SM Garrido","year":"2001","unstructured":"Garrido SM et al (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29(4):448\u2013457","journal-title":"Exp Hematol"},{"issue":"13","key":"8_CR189","first-page":"1252","volume":"22","author":"LJ Bendall","year":"1994","unstructured":"Bendall LJ et al (1994) Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol 22(13):1252\u20131260","journal-title":"Exp Hematol"},{"issue":"9","key":"8_CR190","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41408-021-00547-8","volume":"11","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S et al (2021) Therapeutic targeting of the inflammasome in myeloid malignancies. Blood Cancer J 11(9):152","journal-title":"Blood Cancer J"},{"issue":"6","key":"8_CR191","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","volume":"120","author":"L Barreyro","year":"2012","unstructured":"Barreyro L et al (2012) Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120(6):1290\u20131298","journal-title":"Blood"},{"issue":"6","key":"8_CR192","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1084\/jem.20180147","volume":"215","author":"K Mitchell","year":"2018","unstructured":"Mitchell K et al (2018) IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med 215(6):1709\u20131727","journal-title":"J Exp Med"},{"issue":"15","key":"8_CR193","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","volume":"132","author":"L Barreyro","year":"2018","unstructured":"Barreyro L, Chlon TM, Starczynowski DT (2018) Chronic immune response dysregulation in MDS pathogenesis. Blood 132(15):1553\u20131560","journal-title":"Blood"},{"issue":"1","key":"8_CR194","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccell.2016.06.002","volume":"30","author":"U Hockendorf","year":"2016","unstructured":"Hockendorf U et al (2016) RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 30(1):75\u201391","journal-title":"Cancer Cell"}],"container-title":["Cancer Treatment and Research","Cancer Immunotherapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-96376-7_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T23:58:14Z","timestamp":1675555094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-96376-7_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783030963750","9783030963767"],"references-count":194,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-96376-7_8","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"type":"print","value":"0927-3042"},{"type":"electronic","value":"2509-8497"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"13 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}